NCT03725722 · Interventional trial
Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over an 8-week Treatment Period in Adult Subjects With Atopic Dermatitis.
Overall registry status Completed
Phase 2
Conditions Atopic Dermatitis
Delaware Valley sites
- Leo Pharma Investigational Site · Philadelphia, PA · Philadelphia County
First posted
Registry updated
Added to the directory